Crispr Therapeutics [CRSP] vs Blueprint Medicines [BPMC] Detailed Comparison

TLDR: Quick Comparison Summary

Based on 11 vital metrics comparison: Crispr Therapeutics wins in 4 metrics, Blueprint Medicines wins in 7 metrics, with 0 ties. Blueprint Medicines appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Crispr Therapeutics Blueprint Medicines Better
P/E Ratio (TTM) -10.50 -120.00 Blueprint Medicines
Price-to-Book Ratio 2.15 24.19 Crispr Therapeutics
Debt-to-Equity Ratio 11.99 208.50 Crispr Therapeutics
PEG Ratio -9.04 -136.38 Blueprint Medicines
EV/EBITDA -4.80 -53.15 Blueprint Medicines
Profit Margin -215.00% -27.70% Blueprint Medicines
Operating Margin -17,158.84% -27.50% Blueprint Medicines
Return on Equity -19.71% -47.71% Crispr Therapeutics
Return on Assets -12.88% -9.75% Blueprint Medicines
Free Cash Flow $-144.68M $-197.22M Crispr Therapeutics
1-Year Return -11.59% 9.02% Blueprint Medicines
Overview
Performance
Valuation
Financials
Short Interest
Dividends

Crispr Therapeutics vs Blueprint Medicines Price History Comparison

Key Statistics Comparison

Loading Statistics...

Performance

Crispr Therapeutics vs Blueprint Medicines Performance Comparison Chart

Loading Price Chart...

Performance Comparison

Loading Performance Data...

Valuation

Valuation History

Loading Valuation History...

Market Capitalization % Change

P/E Ratio (TTM)

Forward P/E

PEG Ratio

Price to Sales (TTM)

Price to Book (MRQ)

Enterprise Value % Change

EV/EBITDA

EV/Revenue

Valuation Metrics

Loading Valuation Metrics...

Financials

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement Comparison (TTM)

Loading Financials...

Short Interest And Ownership

Short Interest And Ownership Metrics

Loading Short Interest And Ownership Data...

Dividends

Dividend Information

Loading Dividend Information...